Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Pharmacyclics
So what: Analysts at both RBC Capital and Global Hunter Securities downgraded shares of Pharmacyclics today. This comes a day after the company announced a licensing deal with a division of Johnson & Johnson
Now what: The deal with J&J includes a $150 million upfront payment and potential for the additional $825 million as the drug passes approvals for several cancers. Analysts obviously aren't applauding the deal and the market has socked Pharmacyclics hard today. Considering the company had negligible revenue and this one deal alone could be worth more than the company's market cap, I think the move is overdone.
Interested in more info on Pharmacyclics? Add it to your watchlist by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.